Search research articles
Contact Us
Filters
Showing results (21-30 of 141) with videos related to
Page
of 15
Sort By:
The Medical Journal of Australia
|
February 10, 2022
Does the FDA-approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?
Andrew Gleason, Scott Ayton, Ashley I Bush
Free Radical Biology & Medicine
|
November 13, 2012
Metallostasis in Alzheimer's disease
Scott Ayton, Peng Lei, Ashley I Bush
Frontiers in Aging Neuroscience
|
July 23, 2013
A delicate balance: Iron metabolism and diseases of the brain
Dominic Hare, Scott Ayton, Ashley Bush, et al.
Psychopharmacology
|
July 25, 2009
Serotonergic lesions of the dorsal hippocampus differentially modulate locomotor hyperactivity induced by drugs of abuse in rats: implications for schizophrenia
Wendy Adams, Scott Ayton, Maarten van den Buuse
Molecular Neurodegeneration
|
April 24, 2025
Apolipoprotein E in Alzheimer's disease: molecular insights and therapeutic opportunities
Abdel Ali Belaidi, Ashley I Bush, Scott Ayton
JAMA Neurology
|
November 29, 2016
Association of Cerebrospinal Fluid Ferritin Level With Preclinical Cognitive Decline in APOE-ε4 Carriers
Scott Ayton, Noel G Faux, Ashley I Bush
Nature Communications
|
May 20, 2015
Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE
Scott Ayton, Noel G Faux, Ashley I Bush, et al.
Cell Chemical Biology
|
October 21, 2017
Nanoscale Imaging Reveals Big Role for Iron in Alzheimer's Disease
Scott Ayton, Simon A James, Ashley I Bush
Journal of Alzheimer'S Disease : JAD
|
June 6, 2018
Iron and Alzheimer's Disease: An Update on Emerging Mechanisms
Darius J R Lane, Scott Ayton, Ashley I Bush
Neurobiology of Disease
|
December 18, 2018
Cerebrospinal fluid ferritin levels predict brain hypometabolism in people with underlying β-amyloid pathology
Ibrahima Diouf, Amir Fazlollahi, Ashley I Bush, et al.
Page
of 15
Search research articles
Search
Showing results (21-30 of 141) with videos related to
Sort By:
Page
of 15
The Medical Journal of Australia
|
February 10, 2022
Does the FDA-approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?
Andrew Gleason, Scott Ayton, Ashley I Bush
Free Radical Biology & Medicine
|
November 13, 2012
Metallostasis in Alzheimer's disease
Scott Ayton, Peng Lei, Ashley I Bush
Frontiers in Aging Neuroscience
|
July 23, 2013
A delicate balance: Iron metabolism and diseases of the brain
Dominic Hare, Scott Ayton, Ashley Bush, et al.
Psychopharmacology
|
July 25, 2009
Serotonergic lesions of the dorsal hippocampus differentially modulate locomotor hyperactivity induced by drugs of abuse in rats: implications for schizophrenia
Wendy Adams, Scott Ayton, Maarten van den Buuse
Molecular Neurodegeneration
|
April 24, 2025
Apolipoprotein E in Alzheimer's disease: molecular insights and therapeutic opportunities
Abdel Ali Belaidi, Ashley I Bush, Scott Ayton
JAMA Neurology
|
November 29, 2016
Association of Cerebrospinal Fluid Ferritin Level With Preclinical Cognitive Decline in APOE-ε4 Carriers
Scott Ayton, Noel G Faux, Ashley I Bush
Nature Communications
|
May 20, 2015
Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE
Scott Ayton, Noel G Faux, Ashley I Bush, et al.
Cell Chemical Biology
|
October 21, 2017
Nanoscale Imaging Reveals Big Role for Iron in Alzheimer's Disease
Scott Ayton, Simon A James, Ashley I Bush
Journal of Alzheimer'S Disease : JAD
|
June 6, 2018
Iron and Alzheimer's Disease: An Update on Emerging Mechanisms
Darius J R Lane, Scott Ayton, Ashley I Bush
Neurobiology of Disease
|
December 18, 2018
Cerebrospinal fluid ferritin levels predict brain hypometabolism in people with underlying β-amyloid pathology
Ibrahima Diouf, Amir Fazlollahi, Ashley I Bush, et al.
Page
of 15